echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huadong Medicine MB-102 injection clinical trial application was accepted

    Huadong Medicine MB-102 injection clinical trial application was accepted

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 9th, Huadong Medicine issued an announcement stating that its wholly-owned subsidiary Sino-American Huadong received the "Notice of Acceptance" approved and issued by NMPA, and the application for the clinical trial of the first class new drug MB-102 injection declared by Sino-American Huadong and MediBeacon Get accepted.


    MB-102 is a fluorescent tracer used to measure the glomerular filtration rate.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.